The state of vascular endothelium, clinical and metabolic features of patients with coronary heart disease combined with nonalcoholic fatty liver disease

N. S. Mykhailovska, L. Ye. Miniailenko

Zaporizhzhia State Medical University, Ukraine

Objective: to study changes in the vascular endothelium state in conjunction with clinical and metabolic features in CHD patients with the concomitant nonalcoholic fatty liver disease.

Methods: cross-cohort analytical study involved 86 patients, the primarily selected group consisted of 34 patients, mean age 60 (57.5; 66) with documented coronary artery disease, stable exertional angina of II-III functional class combined with NAFLD; comparison selected group: 32 patients, mean age 60.5 (51.5; 65.6) with coronary artery disease without NAFLD. The control selected group consisted of 20 healthy individuals.

Results: In patients with coronary artery disease and NAFLD compared with CHD patients without NAFLD was found significantly higher levels of ADMA by 21 % (p<0.05), CRP by 1.63 times (p<0.05), intima-media thickness by 14.28 % (p<0.05). Using ROC-analysis established that levels of ADMA >0.74 mmol/l is the cutting point and has an optimal ratio of sensitivity (80 %) to the specificity (82.9 %) for the diagnosis of vascular remodeling in CHD patients with concomitant NAFLD. The presence of significant direct correlation relationship of ADMA with CRP, total cholesterol, glucose, body mass index, alkaline phosphatase, ALT and significant negative relation of ADMA with HDL were found.

Conclusions: In patients with coronary artery disease, combined with NAFLD structural and functional changes in vascular endothelium (increase in serum levels of ADMA, thickening of intima-media) are observed during activation of systemic inflammation (increased CRP concentration), which is associated with metabolic disorders and liver damage indicators. The value of ADMA in serum prevailing 0.74 mmol/l helps to diagnose structural and functional changes in vascular endothelium in patients with coronary artery disease, comorbid with NAFLD.
v сочетании с НАЖБП, медиана возраста – 60 (57,5; 66); группа сравнения – 32 больных с ИБС без НАЖБП, медиана возраста – 60,5 (51,5; 65,6). Всем больным проводили комплексное обследование в соответствии с общепринятыми стандартами (приказ МЗ Украины № 436 от 03.07.2006). С помощью стандартных наборов реактивов иммуноферментным методом определяли уровень инсулина (Monobind, USA), ассоциированный диметилглицин ADMA (Immundiagnostik, Germany). Всем пациентам определяли толщину комплекса интима-медиа эндотелия сосудов на аппарате eSaote Mylab40 (Италия).

Результаты. Определено, что у пациентов с ИБС и НАЖБП в сравнении с больными ИБС без НАЖБП достоверно больше уровень ADMA, а также CRP — в 1,63 раза (р < 0,05), толщина комплекса интима-медиа — на 14,26 % (р < 0,05). С помощью ROC-анализа установлено, что уровень ADMA >0,74 ммоль/л является точкой отсечения и имеет оптимальное соотношение чувствительности (80 %) к специфичности (82,9 %) относительно диагностики ремоделирования сосудов у больных ИБС с сопутствующей НАЖБП. Выявлено наличие достоверной прямой корреляционной взаимосвязи уровня ADMA с CRP, уровнем общего холестерина, глюкозы, щелочной фосфатазы, АЛТ, индексом массы тела и достоверной обратной связи ADMA с ЛПВП.

Выводы. У больных ИБС, коморбидной с НАЖБП, наблюдаются структурно-функциональные изменения сосудистого эндотелия (увеличение сывороточного уровня ADMA, утолщение комплекса интима-медиа) на фоне активации системного воспаления (повышение концентрации CRP), которые ассоциируются с метаболическими нарушениями и индикаторами поражения печени. Значение уровня ADMA в сыворотке крови, превышающее 0,74 ммоль/л, позволяет диагностировать структурно-функциональные изменения сосудистого эндотелия у больных ИБС, коморбидной с НАЖБП.

**Introduction**

Coronary heart disease (CHD) continues to gain the leading place in the structure of incidence and is one of the prevailing causes of death and disability in the population [1]. Metabolic disorders (diabetes, hypertension, dyslipidemia, obesity) 2–4 times raise the risk of coronary heart disease. Nonalcoholic fatty liver disease (NAFLD) is regarded to be one of the conditions associated with metabolic syndrome causing the deterioration of the quality of life, morbidity, and mortality. The prevalence of NAFLD in western countries is 20–30 %, 2–3 % of which have a progressive course with transformation into nonalcoholic steatohepatitis (NASH), cirrhosis, hepatocellular carcinoma [2].

The leading link in the development of NAFLD is insulin resistance syndrome, characterized by the reduced tissues receptors sensitivity to insulin, resulting in increased synthesis of free fatty acids accumulated in the liver. The free fatty acids, in their turn, break the endothelial function through the following mechanisms: production of free radicals, activation of systemic inflammation, adipocytokine imbalance and dyslipidemia [3].

The endothelial dysfunction that defines thrombogenicity, inflammatory changes, vascular reactivity and the stability of atherosclerotic plaques is directly related to the progression of coronary artery disease and also NAFLD [4]. In NAFLD the endothelial cells of hepatic sinusoid are damaged, the production of cytokines, free radicals and collagen increases, and as a result — the change of sinusoid fenestration, collagenization of Disse’s space and growth of intraparenchymal vascular resistance, which, in its turn, provokes significant hepatic circulation disorders, ischemia development, liver tissue necrosis accompanied by fibrosis of these sites in the liver [5].

Today one of the endothelial dysfunction markers, directly related to both CHD and NAFLD is asymmetric dimethylarginine (ADMA). Intracellular production of ADMA happens through the arginine demethylation by the class of enzymes known as arginine-N-methyltransferase and further proteolysis releases ADMA [6]. ADMA is an endogenous inhibitor of NO-synthe enzyme that catalyzes the conversion of L-arginine into nitric oxide (NO) – a powerful vasodilative agent. ADMA plasma levels are related to its release in the process of protein breakdown and its splitting into dimethylamyn and citrulline under the influence of enzyme dimethylarginine dimethylaminohydrolase (DDAH). DDAH is present in the liver, pancreas, spleen and kidneys, but the liver DDAH plays a dominant role in the utilization of plasma ADMA [7].

Recently the significance of ADMA as a new risk factor for CVD was defined. In The Ludwigshafen Risk and Cardiovascular Health Study — a significant prospective study with an average observation period of 5.5 years it was estimated that the concentration of ADMA plasma levels is associated with mortality from cardiovascular and other causes in patients with stable and unstable angina regardless of known risk factors. [8]. In another study with an observation period of 24 years, Leong et al. (2008) showed the relation between the increased blood ADMA levels and the increase of the frequency of myocardial infarction and stroke in women [9]. Also, the relationship between the content of ADMA and severity of coronary artery disease, the influence of ADMA concentration on prognosis and survival of patients with cardiovascular system disorders was found out [10].

Besides the prevention of the NO synthesis through the competitive braking of eNOS, ADMA may promote further breaking of its enzymatic activity and transformation into the generator of superoxide. It is believed that this ADMA activity contributes further endothelial dysfunction and may play a significant role in the pathogenesis of liver diseases, acting as a source of vessels oxidative stress [11].

However, data on the particularities of concentration changes in ADMA serum level as a marker of endothelial dysfunction, depending on the functional state of the liver in patients with coronary artery disease and concomitant NAFLD are limited; the relationship of ADMA with components of the metabolic syndrome in these patients has not yet been investigated. Thus, the role of endothelial dysfunction in the pathogenesis of CHD comorbid with NAFLD requires further study. The objective of the research: to study changes in the vascular endothelium state in interconnection with clinical and metabolic features in CHD patients with the concomitant nonalcoholic fatty liver disease.
Materials and methods of the research

Cross-cohort analytical study in parallel groups involved 86 patients, the primary group consisted of 34 patients with documented coronary artery disease, stable II–III functional class (FC) exertional angina combined with NAFLD, median age 60 (57.5; 66); comparison group: 32 patients with IBS without NAFLD, median age 60.5 (51.5; 65.6). The control group consisted of 20 healthy individuals, the median age 58 (54; 60). Groups are comparable in age, sex, comorbidities nature, duration of CHD. Before being included in the study, all participants provided written consent. II and FC exertional angina were diagnosed under the classification of the Canadian Heart Association. The nonalcoholic fatty liver disease was determined by ultrasound examination of the liver according to the generally accepted methodology.

Criteria of including into the study: informed consent of the patient, the presence of verified CHD and NAFLD. The excluding criteria: patient with alcoholic liver disease or cirrhosis, autoimmune and viral hepatitis; autoimmune disorders; acute coronary syndrome or acute cerebrovascular accident in less than 3 months prior to the study; decompensated heart failure; oncological diseases.

All the patients with coronary artery disease were subjected to a comprehensive examination under the generally accepted standards (MOH of Ukraine number 436 of 03.07.2006). Anthropometric measurements included the definition of height, weight, body mass index. The study of total cholesterol (W), triglycerides (TG), high-density lipoproteins (HDL), low-density lipoprotein (LDL), blood glucose, the activity of alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), gamma-glutamyltransferase (GGT), thymol test performance, total bilirubin concentration was performed by standard biochemical techniques. To assess the degree of insulin resistance indexes HOMA-IR and CARO were used.

The thickness of intima-media vascular endothelial complex was measured in all the patients on the eSaote Mylab40 (Italy) apparatus. The research of the main head characteristic was measured in all the patients on the eSaote Mylab40 (Italy) apparatus. The exclusion of the patient, the presence of verified CHD and NAFLD. The nonalcoholic fatty liver disease was determined by ultrasound examination of the liver according to the generally accepted methodology.

Due to the analyses of the main clinical characteristics it was found out that in patients with coronary artery disease and NAFLD the reliably higher rates of BMI, waist circumference, SBP were observed in comparison with those in the group of healthy persons and IHD patients without concomitant NAFLD (p<0.05) (Table 1).

In patients with coronary artery disease and NAFLD a reliable increase in the value of BMI by 22.25 % was marked if to be compared with the control group and by 13 % if compared with patients with coronary artery disease (p<0.05). The trend to the increase in levels of total cholesterol and LDL cholesterol, atherogenic index and to the reduction of HDL cholesterol in the intervention

Table 1. Clinical and laboratory characteristics of patients with coronary artery disease depending on the presence of concomitant NAFLD

<table>
<thead>
<tr>
<th>Index. Unit (of measurement)</th>
<th>Control group (n=32)</th>
<th>CHD (n=32)</th>
<th>CHD and NAFLD (n=34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI, kg/m²</td>
<td>26.29 (24.08; 29.26)</td>
<td>28.73 (27.7; 31.88)</td>
<td>32.44 (30.13; 37.62)**</td>
</tr>
<tr>
<td>Waist, sm</td>
<td>80.66 (73.94; 96.42)</td>
<td>89.13 (79.3; 101.6)</td>
<td>94.82 (88.5; 105.1)**</td>
</tr>
<tr>
<td>Systolic BP, mmHg</td>
<td>125.0 (110.0; 130.0)</td>
<td>140.0 (130.0; 145.0)</td>
<td>160.0 (160.0; 170.0)**</td>
</tr>
<tr>
<td>Diastolic BP, mmHg</td>
<td>80.0 (70.0; 90.0)</td>
<td>80.0 (65.0; 90.0)</td>
<td>95.0 (90.0; 100.0)</td>
</tr>
<tr>
<td>General cholesterol, mmol/l</td>
<td>4.84 (4.57; 5.63)</td>
<td>5.01 (4.21; 5.55)</td>
<td>5.67 (4.24; 6.29)</td>
</tr>
<tr>
<td>LDL, mmol/l</td>
<td>2.86 (2.14; 4.29)</td>
<td>3.91 (3.35; 6.1)</td>
<td>3.20 (2.79; 3.57)</td>
</tr>
<tr>
<td>HDL, mmol/l</td>
<td>1.2 (1.12; 1.48)</td>
<td>1.11 (0.75; 1.37)</td>
<td>0.95 (0.86; 1.34)</td>
</tr>
<tr>
<td>TG, mmol/l</td>
<td>1.06 (1.05; 1.13)</td>
<td>1.66 (0.8; 1.95)</td>
<td>2.27 (1.28; 2.75)**</td>
</tr>
<tr>
<td>Atherogenicity index</td>
<td>2.45 (2.05; 3.19)</td>
<td>3.03 (2.13; 3.76)</td>
<td>3.63 (3.42; 3.81)</td>
</tr>
</tbody>
</table>

*: the probability of indexes difference if compared with the control selected group (p<0.05).

**: the probability of indexes difference if compared with the patients with coronary artery disease (p<0.05).
group was observed in comparison with patients with CHD and practically healthy persons. Triglyceride levels in patients with coronary artery disease and NAFLD were significantly 2 times higher than in the control group and by 36% – compared with patients without liver disease (p < 0.05).

In analyzing the parameters of carbohydrate metabolism and insulin resistance (Table 2) the following changes were revealed: by the level of glucose the significant difference between groups was not found; in patients with coronary heart disease associated with NAFLD, there was a significant (p < 0.05) increase in insulin levels as compared to healthy persons (4.75 times) and CHD patients without structural and functional changes in the liver (2.42 times). A similar tendency was observed in terms of HOMA index. Its 5 times increase in comparison with healthy people was revealed, 2.35 times increase in patients with ischemic heart disease, respectively (p < 0.05). CARO index was 3.43 times lower in patients with a core group compared with healthy people and 2 times lower compared with patients without comorbid coronary artery disease pathology (p < 0.05). Revealed violations indicate the development of insulin resistance which is associated with an imbalance of adipocytokines level, typical for this category of patients [12].

Features of the liver functional state in patients with coronary artery disease depending on the presence of concomitant NAFLD are shown in Table 3.

In patients with coronary heart disease associated with NAFLD, there was a significant (p < 0.05) 3.18 times increase in levels of alkaline phosphatase compared to the control group and 1.35 times increase in comparison with patients with IBS without liver pathology. Serum GGT in patients with coronary artery disease with NAFLD was 2 times higher compared with healthy individuals (p < 0.05) but did not differ significantly from the similar characteristic of the compared group. According to other parameters of the liver functional state, significant differences between groups were not found due to the prevalence of patients with steatosis than with steatohepatitis (79.5% vs. 20.5%) in the study group.

Indicators of endothelial dysfunction in patients with coronary artery disease depending on the availability of NAFLD are presented in Table 4.

It was found out that in patients with coronary artery disease NAFLD, the ADMA serum level was 42% higher than in healthy individuals and 21% higher compared with the group of CHD patients without liver disease (p < 0.05); according to the level of CRP the study group patients 5.16 times dominated the control group and 1.63 times the comparison group (p < 0.05). The thickness of intima-media significantly prevailed in patients with comorbid disorders: 1.15 (1.00; 1.2) against 0.94 (0.9; 1.0) mm in patients with CHD and 1.15 (1.00; 1.2) against 0.78 (0.7; 0.8) mm in healthy individuals (p < 0.05). The frequency of registration of intima-media thickening in patients with concomitant coronary artery disease and NAFLD and in the comparison group are shown in Fig. 1.

---

**Table 2. Carbohydrate metabolism and insulin resistance characteristics in patients with coronary artery disease depending on the presence of concomitant NAFLD**

<table>
<thead>
<tr>
<th>Index, Unit (of measurement)</th>
<th>Control group (n = 20)</th>
<th>CHD (n = 32)</th>
<th>CHD and NAFLD (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Glucose, mmol/l</td>
<td>4.20 (4.1; 4.72)</td>
<td>4.35 (3.90; 4.90)</td>
<td>5.00 (4.10; 5.80)</td>
</tr>
<tr>
<td>Insulin, mIU/ml</td>
<td>3.57 (3.43; 5.33)</td>
<td>7.41 (0.57; 13.50)</td>
<td>17.00 (6.33; 22.77)**</td>
</tr>
<tr>
<td>HOMA-IP</td>
<td>0.66 (0.62; 0.99)</td>
<td>1.43 (0.68; 1.73)</td>
<td>3.37 (1.50; 5.80)**</td>
</tr>
<tr>
<td>Index CARO</td>
<td>1.03 (0.83; 1.19)</td>
<td>0.61 (0.38; 0.76)</td>
<td>0.30 (0.22; 0.88)**</td>
</tr>
</tbody>
</table>

*: the probability of indexes difference if compared with the patients with coronary artery disease (p < 0.05).

---

**Table 3. Characteristics of the liver functional state in patients with coronary artery disease depending on the presence of concomitant NAFLD**

<table>
<thead>
<tr>
<th>Index, Unit (of measurement)</th>
<th>Control group (n = 20)</th>
<th>CHD (n = 32)</th>
<th>CHD and NAFLD (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT, umol/l·min⁻¹·h⁻¹</td>
<td>0.55 (0.34; 0.68)</td>
<td>0.61 (0.51; 0.79)</td>
<td>0.73 (0.44; 0.82)</td>
</tr>
<tr>
<td>AST, umol/l·min⁻¹·h⁻¹</td>
<td>0.45 (0.26; 0.63)</td>
<td>0.44 (0.38; 0.58)</td>
<td>0.49 (0.33; 0.72)</td>
</tr>
<tr>
<td>Bilirubin, umol/l</td>
<td>8.0 (3.2; 11.7)</td>
<td>14.35 (10.0; 17.3)</td>
<td>14.45 (8.75; 18.0)</td>
</tr>
<tr>
<td>Thymol test, un.</td>
<td>1.86 (0.76; 3.43)</td>
<td>3.02 (2.0; 3.86)</td>
<td>2.33 (1.61; 3.0)</td>
</tr>
<tr>
<td>Alkaline phosphatase, nmol/l</td>
<td>1165.71 (1016.32, 1278.10)</td>
<td>2802.59 (2602.41, 2894.99)</td>
<td>3772.72 (3572.54, 4850.64)**</td>
</tr>
<tr>
<td>Gamma glutamyl transferase, un/l</td>
<td>5.88 (2.72; 10.14)</td>
<td>8.9 (4.45; 11.1)</td>
<td>11.62 (6.88; 26.7)</td>
</tr>
</tbody>
</table>

*: the probability of indexes difference if compared with the patients with coronary artery disease (p < 0.05).

---

**Table 4. Indicators of endothelial dysfunction in patients with coronary artery disease depending on the availability of NAFLD**

<table>
<thead>
<tr>
<th>Index, Unit (of measurement)</th>
<th>Control group (n = 20)</th>
<th>CHD (n = 32)</th>
<th>CHD and NAFLD (n = 34)</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRP, mg/l</td>
<td>0.6 (0.4; 0.8)</td>
<td>1.9 (1.5; 2.5)</td>
<td>3.1 (3.1; 4.3)**</td>
</tr>
<tr>
<td>ADMA, umol/l</td>
<td>0.5 (0.44; 0.53)</td>
<td>0.71 (0.63; 0.76)</td>
<td>0.86 (0.84; 0.96)**</td>
</tr>
<tr>
<td>IMT, mm</td>
<td>0.78 (0.7; 0.8)</td>
<td>0.94 (0.9; 1.0)</td>
<td>1.15 (1.00; 1.2)**</td>
</tr>
</tbody>
</table>

*: the probability of indexes difference if compared with the patients with coronary artery disease (p < 0.05).
The analysis of the frequency of registration of the intima-media thickening showed that among patients of the main group there were 15% more individuals with the index IMT ≥0.9 mm ($\chi^2 = 4.89; p < 0.05$).

To assess the effectiveness of determining the ADMA serum levels as a marker of structural and functional changes in blood vessels in ischemic heart disease, comorbid with NAFLD the ROC-analysis was conducted. The defining of the presence of the intima-media complex thickening was used as a reference method. The ROC-curve area was built, the area under which was equal to AUC = 0.91 subject to a 5% confidence interval: 0.825 to 0.966.

It was determined that the level of ADMA >0.74 mmol/l, is the cutting point and has an optimal ratio of sensitivity (80%) to specificity (82.9%) considering the diagnostics of vascular remodeling. This statistically justified threshold value is the highly reliable factor associated with structural and functional changes in vascular endothelium in patients with coronary artery disease combined with NAFLD. The area under the ROC-curve of more than 0.8 indicates a statistically reliable threshold value with high quality of chosen model.

The presence of correlation relationship of ADMA concentrations with CRP levels ($r = +0.56; p < 0.05$), testifying the role of immunoinflammatory changes in the development of endothelial dysfunction in patients with coronary artery disease concomitant with NAFLD was defined. The results obtained coincide with the modern research confirming the role of systemic inflammation as a leading pathophysiological mechanism in the nonalcoholic fatty liver disease, which contributes to the development of endothelial dysfunction and, consequently, to the progression of coronary artery disease [13].

In patients with coronary artery disease and NAFLD the reliable direct relationship of ADMA rate with classic risk factors for cardiovascular disease was revealed: total cholesterol ($r = +0.47; p < 0.05$), BMI ($r = +0.53; p < 0.05$), glucose ($r = +0.65; p < 0.05$), and the significant negative relationship of ADMA with HDL ($r = -0.48; p < 0.05$); IMT with BMI ($r = +0.56; p < 0.05$), glucose ($r = +0.43; p < 0.05$), the level of SBP ($r = +0.46; p < 0.05$), thus specifying the association of endothelial dysfunction with the development and progression of metabolic disorders in this comorbid conditions. The relationship of ED with metabolic disorders was found in the works of other scholars. It is proved that carbohydrate metabolism disorders, IR and obesity are important factors of ED and early vascular aging (EVA-Syndrome) [14,15]. According to N. M. Hromnatska (2014), the development of ED and increase in arterial stiffness is a versatile reaction of tissue to IR and inflammatory stress, inherent both to CHD and NAFLD [16].

The presence of relationships between the ADMA endothelial dysfunction marker and liver damage principal indicators in patients with coronary artery disease, combined with NAFLD was established: ALT ($r = +0.71; p < 0.05$), ALT ($r = +0.76; p < 0.05$); IMT levels of GGT ($r = +0.55; p < 0.05$), which goes with the literature. Thus, A. P. Schekotova (2013) in her study traced the authentic relationship of endothelial damage markers and indicators of the cholestatic syndrome. The authors, however, suggest that endothelial damage at the same time depends not so much on the functional state of the liver and hepatocytes defeat as on the impact of hostility factors (inflammation, viral agents) directly on the endothelium [17]. However, according to other authors (O. B. Dynyk, L. A. Stadnyuk, 2008), it was estimated that generally accepted indicators of endothelial dysfunction (vasodilation endothelium, circulating endothelial cells) progressively worsen with the increasing severity of liver disease and are associated with changes in its functional state [18].

**Conclusions**

1. In patients with coronary artery disease, combined with NAFLD, an increase in serum levels of asymmetric

---

**Fig. 1.** The frequency of registration of intima-media thickening in patients with concomitant coronary artery disease and NAFLD and in the comparison group.

*: the probability of indicators difference if compared with patients with coronary artery disease, according to the $\chi^2$ criterion, ($p < 0.05$).

**Fig. 2.** The results of ROC-analysis of the ADMA serum levels relationship with intima-media complex thickness in patients with coronary artery disease combined with nonalcoholic fatty liver disease.
dimethylarginine, CRP, and thickening of intima-media segment compared with patients with CHD without concomitant liver disease are observed, thus indicating the presence of endothelial dysfunction in the background of activation of systemic inflammation in these patients.

2. The level of ADMA >0.74 mmol/l with sensitivity (80%) and specificity (83 %) allows diagnosing structural and functional changes in vascular endothelium in patients with coronary artery disease combined with NAFLD, thus indicating that its value is a marker of vascular remodeling in these patients.

3. Markers of structural and functional state of endothelium in patients with coronary artery disease and NAFLD are associated with the metabolic disorders (BMI, waist volume, SBP, levels of glucose, cholesterol, insulin resistance) and indicators of liver disease (ALT, alkaline phosphatase, GGT) indicating the generality of pathogenetic mechanisms of the development and progression of these comorbid disorders.

Prospects for further research: identification of opportunities for pharmacological correction of endothelial dysfunction and metabolic disorders found in patients with CHD associated with nonalcoholic fatty liver disease is a promising direction for our further research.

References


Information about authors:

Mykhailovska N. S., MD, PhD, DSc, Professor, Head of the Department of General Practice – Family Medicine, Zaporizhzhia State Medical University, Ukraine.

Minailenko L. E., PhD Student at the Department of General Practice – Family Medicine, Zaporizhzhia State Medical University, Ukraine.

Vідомості про авторів:

Михайлівська Н. С., д-р мед. наук, професор, зав. каф. загальної практики – сімейної медицини, Запорізький державний медичний університет, Україна.

Міняйленко Л. Є., аспірант каф. загальної практики – сімейної медицини, Запорізький державний медичний університет, Україна.

Conflicts of Interest: authors have no conflict of interest to declare.

Надійшло до редакції / Received: 21.02.2017
Послідовність роботи / Revised: 28.02.2017
Прийнято до друку / Accepted: 01.03.2017